Please try another search
Wilson Therapeutics AB publ, a biopharmaceutical company, develops various therapies for patients with rare copper-mediated disorders primarily in the United States and the European Union. It is developing its lead product WTX101, a bis-choline tetrathiomolybdate copper-protein binding agent that is in the Phase III clinical studies for the treatment of Wilson disease, as well as pre-clinical studies for the treatment of amyotrophic lateral sclerosis. The company was founded in 2012 and is headquartered in Stockholm, Sweden. As of June 8, 2018, Wilson Therapeutics AB publ operates as a subsidiary of AstraZeneca PLC
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review